

Aeglea BioTherapeutics, Inc.
Form 8-K
May 03, 2019

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 30, 2019

AEGLEA BIOTHERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-37722	46-4312787
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

901 S. MoPac Expressway

Barton Oaks Plaza One

Suite 250

Austin, TX	78746
(Address of principal executive offices)	(Zip Code)

Edgar Filing: Aeglea BioTherapeutics, Inc. - Form 8-K

(512) 942-2935

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 Par Value Per Share	AGLE	The Nasdaq Stock Market LLC (Nasdaq Global Market)

Item 1.01 Entry into a Material Definitive Agreement.

On April 30, 2019, Aeglea BioTherapeutics, Inc. (the “Company”) entered into a lease agreement (the “Lease”) with Las Cimas Owner LP (the “Landlord”), with a commencement date of April 30, 2019. The Lease premises include approximately 30,000 square feet, located at 805 Las Cimas Parkway, Austin, Texas 78746 (the “Premises”). The Company expects to use the Premises as its new corporate headquarters and for laboratory space. The Lease will expire on April 30, 2028, with a Company option to extend the term of the Lease by an additional five-year term. The aggregate estimated rent payments due over the initial term of the Lease is approximately \$10.7 million.

The Company will post a customary letter of credit in the amount of \$1.5 million as security, which is subject to an automatic reduction per the terms of the Lease. The Landlord also provided the Company with a construction allowance of approximately \$1.0 million.

The foregoing description of the Lease is qualified in its entirety by reference to the Lease, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of Registrant.

The information set forth above in Item 1.01 of this Current Report on Form 8-K regarding the Lease is incorporated into this Item 2.03 by reference.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AEGLEA
BIOTHERAPEUTICS,
INC.

Date: May 3, 2019 By: /s/ Charles N. York II
Charles N. York II
Chief Financial Officer